Altace Will See Challenge From Generic ACE Inhibitors, Not Class Labeling, King Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased attention to benefits of antihypertensives will help Altace and the entire class, King says. “We just have to fight the...battle” on differentiation, CEO Markison says.
You may also be interested in...
Depomed’s Glumetza Q3 Launch Will Be Executed By King
Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.
Depomed’s Glumetza Q3 Launch Will Be Executed By King
Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.
Cobalt's Altace Generic Gets FDA Approval, 180 Days Of Exclusivity
King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.